NZ260506A - Delaying and/or reducing appearance of nucleoside analogue resistance in a virus by administering matched or mismatched dsrna prior to nucleoside analogue therapy - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £60506 New Zealand No. 260506 International No. PCT/ TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 16.04.1991; Complete Specification Filed: 18.03.1992 Classification:^) A61K31/70 Publication date: 24 July 1997 Journal No.: 1418 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of Invention: USE OF DOUBLE-STRANDED RNAS IN THE PREPARATION OF MEDICAMENTS FOR ABROGATION OF VIRAL RESISTANCE TO NUCLEOSIDE ANALOGUES Name, address and nationality of applicant(s) as in international application form: HEM PHARMACEUTICALS CORP, a Delaware corporation of One Penn Center, Suite 660, Philadelphia, Pennsylvania 19103, United States of America 260506 Under the provision* of Reg«»» talion 23 (1) tha • • — pGfiWpfefe; SfncMcatkwi hap b««n ariM ifafnrf ». 16..IWfic. i»«..

— NO DRAWINGS NEW ZEALAND PATENTS ACT, 1953 Divided out of Application No.: 242033 Date: 18 March 1992 COMPLETE SPECIFICATION USE OF DOUBLE-STRANDED RNAs IN THE PREPARATION OF MEDICAMENTS FOR ABROGATION OF VIRAL RESISTANCE TO NUCLEOSIDE ANALOGUES We, HEM PHARMACEUTICALS CORE, a corporation of the State of Delaware, United States of America of One Penn Center, Suite 660, Philadelphia, Pennsylvania 19103, United States of America hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- (followed by page la) N.Z. PATENT OFFICE _______ -9 MAY 1997 . RECEIVED la 26 0 5 Nucleoside analogues are commonly employed antiviral agents, particularly against retroviruses. Viruses undergo genetic changes, or mutations, leading to relative resistance to these antiviral agents. When resistance occurs, the viruses multiply more quickly and the underlying disease accelerates. By deploying dsRNAs relatively early in the infection, the rate of emergence of viral resistance is reduced. Even later in the infection when genetic mutation has already occurred, dsRNAs restore susceptibility of the viruses to otherwise ineffective antiviral agents. This can be seen clinically by the unexpected result that long term use of the two modalities, in combination, causes greater recovery of host immune function, and less detectable virus, than is seen with either class of antiviral agent applied by itself.

Prolonged therapy of viral diseases, particularly retroviral disorders, is associated with emergence of viral resistance (references 1 and 2). Ideally, therapeutically employed the nucleoside analogues are incorporated into viral genetic information which thereby becomes faulty or incomplete, leading to a reduction in efficiency of the viral growth cycle. Defective, or incomplete, viral progeny are formed of reduced infectivity 260 506 2 potential. However, by modifying its genetic makeup, the virus may emerge relatively resistant, thereby generating infectious progeny even in the presence of nucleoside analogues. Typical genetic changes occur in the polymerase gene (i.e., the viral component which directs incorporation of the antiviral nucleoside in the first place) allowing the virus to escape from these forms of antiviral blockade. The best studied case to date is the interaction between retroviruses, e.g., HIV (human immunodeficiency virus) and 3'-azido-3'-deoxythmidine, also called AZT or zidovudine. The mutation(s) leading to resistance to AZT often confers simultaneous resistance to various other drugs, such as (but not limited to), dideoxyinosine (DDI) and dideoxycytidine (DDC).

Disclosed are procedures for delaying, reducing or both delaying and reducing the appearance of nucleoside analogue resistant virus in a patient having an HIV infection (HIV positive) by administering an effective amount over a suitable time of a mismatched dsKNA prior to therapy with a nucleoside analogue. These procedures serve to sensitize the patient to the later, in terms of the course of the HIV infection, administration of a nucleoside analogue antiretroviral agent if and when it is required.

Also described are therapeutic procedures for ameliorating the morbidity of the peripheral blood mononuclear blood cells (PBMC), notably the T4 or CD 4 lymphocytes, of a patient infected with a 3 26050 retrovirus that has become resistant to nucleoside analogues by administering an effective amount of a mismatched dsRNA to the patient.

BRIEF DESCRIPTION OF THE INVENTION The present invention provides a use of matched or mismatched dsRNA in the preparation of a medicament for concurrent or sequential administration with a nucleoside analogue antiretroviral agent for preventively delaying or reducing the appearance of nucleoside analogue resistant virus in a patient having an HTV infection.

Also described but not claimed is a method of preventively delaying or reducing the appearance of nucleoside analogue resistant virus in a patient having an HIV infection, comprising administering to said patient an effective amount of a mismatched dsRNA.

In one embodiment the patient is administered a nucleoside analogue antiretroviral agent subsequent to therapy with said mismatched dsRNA.

Preferably, the nucleoside analogue antiretroviral agent is administered in a medium to long term period subsequent to therapy with said matched or mismatched dsRNA.

The dsRNA may be a complex of a polyinosinate and a polycytidylate containing a proportion of uracil bases or guanidine bases, e.g., from 1 in 5 to 1 in 30 such bases (poly I • poly(C4 2gx>U or G)).

The dsRNA may be of the general formula rIn*r(C1114,U)n or rIn*r(ci2'U)iT other suitable examples of dsRNA are discussed below.

By "mismatched dsRNA" are meant those in which hydrogen bonding (base stacking) between the counterpart strands is relatively intact, i.e., is interrupted on average less than one base pair in every 29 consecutive base pair residues. The term "mismatched dsRNA" should be understood accordingly.

N.Z. PATENT OFFICE f-9 MAY 1997 (followed by page 3a) 260506 3a The mismatched dsRNAs preferred for use in the present invention are based on copolynucleotides selected from poly (Cn,U) and poly (Cn,G) in which n is an integer having a value of from 4 to 29 and are mismatched analogs of complexes of polyriboinosinic and polyribocytidilic acids, formed by modifying rIn*rCn to incorporate unpaired bases (uracil or guanidine) along the polyribocytidylate (rCn) strand. Alternatively, the dsRNA may be derived from (followed by page 4) 260506 backbone of polyriboinosinic acid (rln), by including 2'-0-methyl ribosyl residues. The mismatched complexes may be complexed with an RNA-stabilizing polymer such as lysine and cellulose. These mismatched analogs of rl *rC , n n preferred ones of which are of the general formula rIn' (Cll-14'U)n or rIn:|-*r(C29/G)n' are described bY Carter and Ts'o in U.S. Patents 4,130,641 and 4,024,222 the disclosures of which are hereby incorporated by reference. The dsRNAs described therein generally are suitable for use according to the present invention. The preferred mismatched dsRNA is rl •(Cn ,„,U1 or AMPLIGEN® of HEM n 11—14 'n Research, Inc. of Rockville, MD, USA, available as a lyophilized powder.

Other examples of mismatched dsRNA for use in the invention include: - poly (I • poly (C4,U) poly (I • poly (C7,U) poly (I • poly <C13'U> poly (I • poly <C22'U> poly (I • poly <C20'G> poly (I • poly (C2g/G) and poly (I * Po1* CP23 G>P Another class of dsRNAs suited to the practice of this invention are short dsRNAs of defined 260 5 0 6 structure, for example oligonucleotides of the formula: .5' lock- (I) -lock 3' n 3'lock-(C) -lock 5* m where m and n are each more than 5 and less than 100, I is inosine monophosphate, C is cytidine monophosphate, and where the locks in one strand are complementary to locks in the opposite strand, or an oligonucleotide of the structure: 'lock-[(I)xA]j-lock 31 3 ' lock-[ (C) U],-lock 3' y K where x and y are each more than 5 and less than 25, j and k each at least 1 and less than 10, I and C are as identified above, A is a nucleotide which is not I, and U is a nucleotide which base pairs with A.

Alternatively, the short oligonucleotide may have the structure: ,(I)n-hinge-(C)in3' where n, m, I and C are as defined above.

These oligonucleotides may have substitutions in one strand not complementary to nucleotides in the opposite strand. Preferably these oligonucleotides 260 506 6 are stabilized by internal registers of complementary heteropolymer and desirably the lock or hinge or both contain regions of complementary heteropolymer.

These oligonucleotides desirably have single-stranded tails. These oligonucleotides are described in PCT/US89/02172.

Patients are treated with intravenous infusions of 200 to 700 mg of rl'^C^ _^,U) as required, e.g., once a week to as often as daily in accordance with their clinical improvement. The amount of dsRNA administered and the frequency of administration will provide a level of from 0.01 to 1,000 micrograms of dsRNA per milliliter of the patient's systemic blood circulation immediately following administration measured at a point distal from the point of infusion.

Illustrative nucleoside analogue antiviral agents include Zidovudine (azidothymidine, RETROVAR® or AZT as commonly used herein) which is 31-azido-3'-deoxythymidine, a nucleoside analogue antiviral for the systemic treatment of acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) caused by human immunodeficiency virus (HIV, HTLV-I, HTLV-II, HTLV-III, LAV, ARV and the like designators for various strains). The usual adult dose is 200 mg every four hours, around the clock. For a 70 kg patient, the corresponding dose is 2,9 mg per kg of body weight every four hours.

Doses up to 60 mg per kg of body weight daily have 7 260 5 0 been used. Usually less than the normal and customary amounts of the nucleoside analog retroviral is used when coadminstered with a mismatched dsRNA, as illustrated further in the discussion that follows.

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a table showing the time in months to death or "full blown" AIDS for 298 patients ins terms of proportion of the patients free of critical HIV-related events comparing with AZT treatment "early" (square boxes) before symptoms occurred or "late" (circles) after symptoms occurred.

Fig. 2 compares the early use of a dsRNA or its concurrent use with AZT in controlling retroviral growth as compared to rapid retroviral growth in the case of AZT alone.

Fig. 3 compares the relative effects of a dsRNA and AZT as monotherapies with placebo and dsRNA and AZT as a combinational therapy in long term maintenance of CD4 cells in HIV disease in median change in CD4T lymphocytes over the indicated number of weeks.

Fig. 4 relates the number of days of combinational (AZT and dsRNA) therapy to the percent change in mean T4 level showing that the dsRNA Ampligen® extends the period of T4 cell stabilization in HIV disease over that expected with AZT alone. Median does for each member of the combination are indicated. 8 260 506 Fig. 5 is a graph relating the number of days on the combined Ampligen® and AZT regimen to the mean percent change (increase) in T4 cells showing that Ampligen® increases and/or stabilizes T4 cell levels in HIV disease beyond the time period in which AZT is effective.

Fig. 6 is a graph relating the proportion of HIV patients free of critical events over a period of 12 months for placebo, AZT alone, Ampligen® monotherapy and the combinational therapy of Ampligen® and AZT.

In Figures 4 and 6 the number of patients is indicated near the relevant data point in parenthesis, in Figures 3 and 5 it is indicated by N=.

In Figure 2, HIV co-culture was performed as described in reference 3 using peripheral blood mononuclear (PBMC) cells from cases 1 and 3. After 4, 7 and 14 days of co-culture, PBMC were harvested and dissolved in a guanidine cyanate solution used to dissolve cells and release viral materials. HIV RNA was measured by molecular hybridization as described in more detail below.

Figure 1 shows the development of critical events (development of full blown AIDS or death) in a well-publicized Veterans' group of HIV infected subjects treated either "early" (e.g., before symptoms occurred such as weight loss, night sweats, etc.) or "late" (i.e., after such symptoms occurred including HIV-associated infections caused by fungi or bacteria) with AZT. 260506 9 It is apparent from Fig. 1 that the "early" taking of AZT does not prolong life. Samples of blood taken from individuals who developed critical events show an enrichment in concentration of AZT resistant virus (hereafter referred to as AZT ) whereas patients who remained free of critical events during the approximately 40 month observation interval generally had more AZT sensitive (AZT ) virus.

Below, I characterize more fully the relative AZT sensitivities of typical HIV isolates taken from individuals whose disease progresses despite AZT therapy and compare these results with viral isolates including hepatitis virus from patients whose disease is under relatively better control. It is apparent that emergence of AZT11 virus contributes a foreshortened life span. Typical human retroviruses including HTLV-1, HTLV-2 and HTLV-3 and viruses which multiply by similar mechanisms include certain hepatitis viruses.

I describe herein a method of treatment which ameliorates this presently unsolvable problem. The method can be practiced in multiple ways including: (a) reducing p the emergence of AZT by utilizing specific classes of dsRNAs before exposure of the virus to AZT or other analogues and (b) overcoming the lethal TJ properties of AZT HIV (or other virus resistant analogues), by adding back dsRNA to the regimen. The dsRNA/nucleoside analogue regimen shows unexpected therapeutic synergy against AZT HIV without a N.Z. PATENT OFFICE £■9 MAY 1997 . RECEIVED 260 5 0 corresponding synergistic toxicity and thus is a truly unique and unexpectedly useful combination of drugs which becomes life saving when used correctly.

Insight as to how combined Ampligen®-AZT treatment reduces HIV-viral burden was obtained by my studies in which cell free virus obtained from patients receiving either Ampligen® or AZT monotherapy or Ampligen®-AZT combinational treatment were used to infect fresh human peripheral blood cells which were previously exposed to Ampligen®, AZT, or Ampligen® and AZT. Virus from the patient who received only AZT monotherapy for more than one year was insensitive to AZT (0.5nM AZT » 4% inhibition; ED,0 < 5|oM) but was as sensitive to Ampligen® alune as wild type HIV-virus (5ng/ml. Ampligen® = 80% inhibition; EDB0 < 0.5ng/ml.). In addition, the Ampligen®-AZT combination produced greater inhibition of HIV (93%) than Ampligen® alone. Virus from the patients who received Ampligen® alone or the Ampligen®-AZT combination showed relative resistance to AZT sensitivity to Ampligen® and even greater sensitivity to the Ampligen®-AZT combination. When results with many different viral isolates were compared from patients on different schedules of therapy, it became apparent that virus from patients who received Ampligen® before exposure to AZT were more sensitive to AZT (and other nucleoside analogues as well) than the viruses derived from patients who received AZT first. 260 506 li TABLE 1 - DRUG RESISTANCE OF HIV ISOLATES HIV Isolate Ampligen® EDS o (ua/ml) AZT ED j o (ua/molar) Combination Index AZT Phenotvoe HI12-2 2 .03 0.5 sensitive 6910-6 3 2 0.2 resistant Case #1 1 0.6 0.4 partially resistant Case #2 1 0.2 0.2 partially resistant Case #3 .5 >5 o • to resistant Case #4 1 >5 00 • o resistant Case #5 .5 >5 o • to resistant Case # 6 2 >5 0.3 resistant a = AZT-Ampligen® interaction was determined by isobole analysis (reference 4). The Combination Index (CI) is defined as CI + (A /A ) + (B /B ), OS c s where A and B are the concentrations of the drugs c c used in the combination treatment, and A and B are s s the concentrations of the drugs which, when used alcne, give the same effect as the combined treatment. When CI < 1, the drugs are synergistic, when Ci = 1, the drugs are additive, and CI > 1, the drugs are antagonistic. EDS0 is the in vitro dose which inhibits virus multiplication by 50%. 260506 12 In Fig. 2, I show a typical embodiment whereby the early use of Ampligen®, or its use concurrently with AZT, in fact results in substantial benefit in terms of lowering the bodily concentration of harmful virus such as retrovirus. The rapidly increasing production curve of viral RNA (ribonucleic acid) shown with the open circles is indicative of uncontrolled viral growth, whereas the two flat lines illustrate good control of virus production by the combinational approach. The open circles in Fig. 2 illustrative of rapidly developing AZT virus, are thus symbolic of the typical patient in Fig. 1 who, when given AZT alone, proceeds to advance into the more terminal stages of disease.

Certain dsRNAs, notably mismatched dsRNAs, showed synergistic' inhibition of retroviruses, when combined with AZT (or other nucleoside analogues) regardless of the drug resistance phenotype (Table 1). H112-2 and 6910-6 are well characterized HIV prototype clones displaying typical sensitivity and resistance, respectively. Whereas, cases #1 through #6 are viruses isolated from specific patients exposed to various regimens (e.g., patients # 1, 2, and 3 are the same as those in Fig. 2, and patients 4, 5 and 6 were treated initially with AZT alone as suggested by Fig. 1).

When I utilized the combination of drugs together clinically, the results were again unexpected and not at all predictable from the observed clinical results of the two drugs given N.Z PATENT OFFICE -9 MAY 1997 RECEIVED 260 5 13 singly (monotherapy). For example, AZT (and other analogues) given alone results in a transitory increase in certain immune cells (reference 5), termed CD4 cells, which are among the immune cells most favored for attack by certain retroviruses and certain herpes viruses (especially HHV 6). After the transitory increase (seen at around 12-16 weeks), the immune cell number deteriorates as HIV proliferates t> and AZT HIV emerges (Fig. 3). The number in parentheses refers to number of subjects studied. By comparison, Ampligen® alone causes a horizontal "line" of CD4 cell number overtime (Fig. 30, e.g., the immune cell number neither increases nor decreases (in other words, cell number is stabilized) at Ampligen® doses of approximately 400 to 500 mg given twice weekly by IV infusion.

Patients receiving AZT monotherapy took 200 ing. orally every 4 hours, daily (1200 mg./day). Patients in the Ampligen® monotherapy group received a minimum of two IV infusions weekly (mean dose range of 463-555 rag. weekly). [Patients receiving the combinational treatment shown in Fig. 4 were also infused with typical Ampligen® doses of 400 mg. twice weekly with an average concomitant AZT daily dose ranging between 300 and 540 mg].

The trends in the median change in T4 lymphocyte for the placebo and AZT monotherapy treatment (after 16 weeks.) groups are consistent with evidence that the course of the disease is inexorably downhill. Without effective therapeutic 260 5 14 intervention, the median change in placebo patient lymphocyte counts declines. After an initial increase, even patients receiving AZT monotherapy experienced a deterioration in their mediem T4 cell D counts and AZT HIV appears. This decline from Week 12 onward appears to parallel that seen with the placebo patients.

Comparison of the slopes by the statistical method of linear regression lines constructed from the change in median T4 cells from week 12 onward for the AZT monotherapy and placebo groups showed they were significantly different (p < 0.01 and p < 0.01, respectively) than a slope of 0 which represents "no change" in median T4 cell levels. "No change" typically represents a stabilization of immunologic disease, a "negative slope" represents disease deterioration, but the most desirable outcome is a positive slope suggestive of disease (immune) recovery, and this could not be achieved by the monotherapy regimens studied.

The Ampligen® alone abrogates the expected CD4 decline after twelve weeks of AZT Monotherapy of Placebo. The slope of the serial median CD4 level regression line during Ampligen® treatment is not statistically different from a horizontal line reflecting no CD4 cell loss over time Slope Comparison With Horizontal (no change) p Value Ampligen® not significant p > 0.2 260 506 AZT Placebo significant significant p < 0.01 p < 0.01 Ampligen® monotherapy (Fig. 3) abrogates the severe decline in median T4 lymphocytes seen in both placebo patients and in AZT treated patients (after a transitory twelve week rise) but the average T4 level did not increase. Moreover, in the Ampligen® group, the small (statistically insignificant) decline in median T4 lymphocytes observed at one year (Fig. 3) can be readily reversed thereby bringing about an even more durable T4 stabilization by increasing the dose to above 200 mg. twice weekly (data not shown). The slope of a regression line constructed from the change in median T4 cells observed from week 12 onward in the Ampligen® monotherapy group was not significantly different from 0 thereby indicative of disease stabilization. The Ampligen® monotherapy, AZT monotherapy, or placebo treated groups shown in Fig. 3 had approximately equivalent median and mean absolute T4 (also called CD4) lymphocyte levels. I then compared them with a new group that received combined Aif.pligen® and AZT treatment. The new group had in fact lower (approximately 33%) median and absolute levels of this prognostic indicator of the progression of HIV infection, thus indicating they were at greater risk of death or other "critical events". 16 260 5 0 The relative effects of Ampligen® and AZT in long term maintenance of CD4 cells per mm3 in HIV disease is shown in the following table.

TABLE 2 Treatment Number of Patients Baseline Median Mean Median Absolute CD4 Cell Change at 1 Year Ampligen® + AZT 11 201 248 + 15 Ampligen® alone 54 311 350 -15 AZT alone 260 350* 355 -28* Placebo 253 350* 356 -59* ♦Estimate based on summary data in Ref.

As noted in Fig. 3, on completion of 1 year of treatment, median absolute T4 lymphocyte counts declined 59 cells (approximately 4.9 cells per month) in the patients who received placebo; declined 28 cells (approximately 2.3 cells per month) in patients who received AZT monotherapy; and declined slightly, 15 cells (approximately 1.25 cells per month), in patients who received Ampligen® monotherapy.

However, the group that received the combinational Ampligen® and AZT therapy, which had the lowest pretreatment median and mean absolute T4 lymphocyte levels (therefore being at the greatest risk) 17 260 506 actually experienced an increase in median absolute T4 cell level of 15 cells even after one year of combination regimen. These results are summarized in Table 2 and provided in more detail in Fig. 4.

Figure 4 demonstrates the serial changes in median T4 lymphocyte levels during the 1 year of combination treatment which should be compared with Ampligen® monotherapy, AZT monotherapy, and placebo effects of Fig. 3. . The baseline for comparison is calculated from the average of the patients' serial absolute T4 lymphocyte counts measured during the three month period immediately before starting the combined therapy.

The increase observed in the first ninety day period is consistent with that previously reported for the initiation of AZT monotherapy as observed in Figure 3 above. However, the subsequent increases, seen from 180 to 540 days of the combined thorapy, are statistically significant and are not observed in patients receiving AZT monotherapy. (A non-parametric analysis confirmed the statistically significant (p<0.05) increase in T4 counts at 1 year. This analysis was performed because of the possibility that the T4 levels were not normally distributed due to the relatively small sample size. ) Thus, the duration of the T4 lymphocyte increase is longer than the 3-6 month transient increase expected from AZT monotherapy and must be attributed to the presence of dsRNA. In addition, this effect was seen with relatively low doses of 18 260 5 both dsRNA and AZT. This observation is consistent with previous findings that at a dose as low as 200 mg. IV twice weekly for 1 to 4 months, Ampligen® monotherapy stabilized the T4 cell decline expected in untreated HIV infected patients (T4 = 60-300 cells/mm3), and that this effect was sustained when patients continued this treatment for 5-8 months (Fig. 3).

A regression line (Figure 5) was constructed from the mean percentage change in T4 Lymphocyte counts over 135 to 630 days of combined dsRNA and AZT therapy. The average of each patient's serial T4 lymphocyte counts during 91-180 days of the combined treatment regimen served as the baseline for determining the percentage changes. This baseline was selected as a point after which AZT's anticipated effect on T4 levels typically has dissipated.

Using statistical methods, the positive slope of the regression line and the slopes of the 95% confidence limits indicate that the combined Ampligen® and AZT therapy successfully abrogated the long-term T4 cell decline expected in untreated patients (4-6 cells/month) or those on long term (> 6 month) AZT monotherapy. Thus the combination treatment in fact sustained T4 levels indefinitely and for much longer time periods than previously observed with AZT monotherapy and this illustrates a basic utility of my invention on nucleoside resistant viruses, especially retroviruses. 260506 19 Finally, Figure 6 corroborates the utility of my invention by presenting the proportion of patients progressing to an AIDS-defining opportunistic infection/lymphoma ("critical event") while receiving placebo, AZT monotherapy, Ampligen® monotherapy, or Ampligen® and AZT combinational therapy.

As indicated in Figure 6, approximately 10% of the patients receiving placebo experienced a critical event during the 12-month observation period. The number of patients at the beginning, month 6 and month 12 of the study are indicated parenthetically. Of the patients receiving AZT, approximately 4% experienced a critical even during that period. Of particular note, was the avoidance of the expected tumor formation seen with AZT given alone (reference 6) by the combined treatment. Further no patient in this study with an absolute T4 lymphocyte count greater than 115 cells/mm3 on entry experienced a critical event while receiving Ampligen® with concomitant AZT, even though they were at great risk to do so due to markedly deteriorated immune systems before beginning the combinational regimen having a median CD4 level of only 201 at baseline (Table 2).

In concert with practicing this method of treatment, lymphokines such as interleukins and interferons may be judiciously added after the foundation of control of viral replication is in place.

N.7. >J OFFICE -9 MAY 1997 ! U'CGiVED 260 5 REFERENCES CITED 1. Larder, B. A. et al pp. 436-441 Antimicrobial Agents and Chemotherapy. Vol. 34, March 1990. 2. Larder, B. A. et al. pp. 1731-1734, Science, Vol. 243, 1989. 3. Jackson, J.B. et al. pp. 1416-1418. Journal Clin. Microbiology, Vol. 216, 1990; Thompson, J. D. et al. pp. 371-378, Analytical Biochem. Vol. 182, 1989. 4. Berenbaum, M.C. pp. 269-333. Advances in Cancer Research Vol. 35, 1981.

. Fischl, M. et al. p. 727-733, Annals of Internal Medicine Vol. 112, 1990. 6. Pluda, J. M. et al pp. 276-282 Annals of Internal Medicine, Vol. 113 (number 4, 1990 260 506

Claims (10)

WHAT WE CLAIM IS:

1. Use of a matched or mismatched dsKNA in the preparation of a medicament for preventively delaying or reducing the appearance of nucleoside analogue resistant virus in a patient having an HIV infection.

2. A use of a matched or mismatched dsRNA in the preparation of a medicament for concurrent or sequential administration with a nucleoside analogue antiretroviral agent for preventively delaying or reducing the appearance of nucleoside analogue resistant virus in a patient having an HIV infection.

3. A use according to claim 1 or claim 2 in which the dsKNA is a matched dsRNA of polyadenylic acid complexed with polyuridylic acid.

4. A use according to claim 1 or 2, in which the mismatched dsRNA is a complex of polyinosinate and polycytidylate containing from Iin5tolin30 uracil or guanidine bases.

5. A use according to claim 4, in which the mismatched dsRNA is rl n .r (Cu_u. U)n or the mismatched dsRNA contains regions of bond breakage and exhibits the favorable therapeutic ratio property of rl n .r(C1W4. U)n.

6. A use according to any one of claims 1 to 5, in which the medicament is formulated to administer an amount of dsRNA which results in a level of from 0.01 to 1,000 micrograms of the dsRNA per milliliter of the patient's systemic blood circulation.

7. A use according to claims 1 or claim 2, in which the dsRNA is a short olignucleotide of defined structure of the formula: 5'lock-(I)n-lock 3' 31ock-(C)m-lock 5' N.Z, PATENT QFRC* -9 MAY 1997 260506 where m and n are each more than 5 and less than 100, I is inosine monophosphate, C is cytidine monophosphate, or 51lock-[(I)XA]j-lock 3' 3'lock-l(C)yU]k-lock 3' where x and y are each more than 5 and less than 25, j and k each at least 1 and less than 10, I and C are as identified above, A is a nucleotide which is not I, and U is a nucleotide which base pairs with A, or 5'(I)n-hinge-{C)m3' where n, m, I and C are as defined above, provided that the locks in one strand are complementary to locks in the opposite strand.

8. A use according to claim 7, in which the oligonucleotide is stabilized by internal registers of complementary heteropolymer and the lock or hinge or both contain regions of complementary heteropolymer.

9. A use according to any one of claims 2 to 8 wherein said nucleoside analogue antiretroviral agent is zidovudine, dideoxyinosine, dideoxycytidine or combinations thereof.

10. A use of a matched or mismatched dsRNA as defined in claim 1 substantially as herein described with reference to any example thereof. END OF CLAIMS N.Z. PATENT OF' r-9 MAY 199? By the authorised agents A. J. PARK & SON ParjS^>Ca3L^